Issues

Chemotherapy increases the mutation burden of normal blood cells in childhood cancer survivors by direct treatment-induced mutagenesis and enhanced activity of processes that are also present during healthy aging.

The patient-derived Clostridioides difficile bacterial strain was found to drive colon tumorigenesis through its toxin TcdB, which induced Wnt signaling and a protumorigenic mucosal immune response.

Single-cell analysis of pre- and postinfusion CD19 CAR-T cells from patients with lymphoma reveals TIGIT as a mediator of CAR-T cell dysfunction that may be alleviated by TIGIT antibody blockade in mouse models of human lymphoma.

Controlling lysophosphatidic acid production in the tumor microenvironment sensitizes ovarian cancer cells to various forms of immunotherapy by unleashing protective type I interferon responses.

BCL10 mutations in diffuse large B-cell lymphoma (DLBCL) fall into two classes, with both conferring BTK inhibitor resistance but only truncation mutations conferring MALT1 dependency, suggesting use of these mutation classes as precision therapy biomarkers.

A small-molecule approach to degrade tumor cell–surface PD-L1 overcomes adaptive immune resistance during MAPK inhibitor therapy, showcasing control of PD-L1 protein stability as an emerging combinatorial strategy.

IL27R signaling suppresses cytotoxic mechanisms in liver cancer, while inhibition of IL27 or IL27R enhances the activation of innate cytotoxic cells leading to anticancer immunity and supporting novel immunotherapeutic applications in hepatocellular carcinoma.

Stress granules (SG) impact obesity-associated pancreatic cancer growth, and targeting the IGF1/IGF1R/S6K1/SRPK2 signaling pathway, which drives SG formation in obesity-associated pancreatic cancer, can selectively impair SGs and tumor growth.